第一三共普拉格雷III期ACS研究取得积极数据
2013-07-17 tomato 生物谷
2013年7月15日讯 /生物谷BIOON/ --第一三共株式会社(Daiichi Sankyo)7月12日在第22届日本心血管疗法年会(CVIT 2013)上公布了在日本急性冠脉综合征(ACS)患者中开展的有关抗血小板普拉格雷盐酸盐(以下简称,普拉格雷,prasugrel)的III期临床研究(PRASFIT-Elective研究)的数据。 复合主要终点(心血管死亡、非致死性心肌梗死、缺血性
2013年7月15日讯 /生物谷BIOON/ --第一三共株式会社(Daiichi Sankyo)7月12日在第22届日本心血管疗法年会(CVIT 2013)上公布了在日本急性冠脉综合征(ACS)患者中开展的有关抗血小板普拉格雷盐酸盐(以下简称,普拉格雷,prasugrel)的III期临床研究(PRASFIT-Elective研究)的数据。
复合主要终点(心血管死亡、非致死性心肌梗死、缺血性中风)发生率:普拉格雷组为4.1%,硫酸氯吡格雷组(以下简称,氯吡格雷,clopidogrel)组为6.7%。非冠脉旁路移植手术(CABG)相关TIMI主要、次要或临床相关出血发生率:普拉格雷组为5.4%,氯吡格雷组为6.2%。非CABG相关TIMI大出血:普拉格雷组为0.0%,氯吡格雷组为2.2%。该项研究的有效性和安全性数据与PRASFIT-ACS研究一致。
目前,第一三共已向日本卫生劳动福利部(MHLW)提交了新药申请(NDA)用于治疗缺血性心脏疾病。(生物谷Bioon.com)
英文原文:Daiichi Sankyo Announces Phase 3 Study Results (PRASFIT-Elective Study) for the Antiplatelet Agent Prasugrel in Japan
Tokyo, Japan (July 12, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the results of a phase 3 clinical study (PRASFIT-Elective study) 1 for the antiplatelet agent prasugrel hydrochloride (hereafter, prasugrel) in Japanese patients with coronary artery disease (stable angina or history of previous myocardial infarction, or myocardial infarction) undergoing elective PCI2 were presented at the 22nd Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics; CVIT 2013.
The incidence of the composite primary endpoint (cardiovascular death, non-fatal myocardial infarction, ischemic stroke) was 4.1 percent in the prasugrel group versus 6.7 percent in the clopidogrel sulfate (hereafter, clopidogrel) group. The incidence of non-CABG (coronary artery bypass graft)TIMI major, minor or clinically relevant bleeding was 5.4 percent in the prasugrel group versus 6.2 percent in the clopidogrel group. The incidence of non-CABG TIMI major bleeding in the prasugrel group was 0.0 percent, while in the clopidogrel group, it was 2.2 percent. The efficacy and safety results of this study are similar to those of the PRASFIT-ACS study3.
Daiichi Sankyo submitted a New Drug Application to the Ministry of Health, Labour and Welfare in Japan4 for the treatment of patients with ischemic heart disease undergoing PCI based on the results of the PRASFIT-ACS and PRASFIT-Elective studies on June 18, 2013.
A Japanese phase 3 trial of prasugrel for patients with ischemic cerebrovascular disease is on-going. This trial is expected to be completed in fiscal year 2014*.
* : From April 1, 2014, to March 31, 2015.
About PRASFIT-Elective study
PRASFIT-Elective is a phase 3, multi-center, randomized, double-blind, double-dummy, parallel group clinical study in Japan to evaluate the efficacy and safety of prasugrel plus aspirin using clopidogrel plus aspirin (as a reference) in patients with stable angina and chronic myocardial infarction undergoing elective PCI. The primary endpoint of the study was the composite incidence of cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke during the 24 week follow-up period. The safety endpoints included non-CABG TIMI major, minor or clinically relevant bleeding. A total of 742 patients were enrolled and received 24 to 48 weeks of either prasugrel or clopidogrel. In current medical practice, patients undergoing elective PCI either start administration with a loading dose (LD) or a maintenance dose (MD), which is decided at the medical institution for each patient. Patients were randomly assigned to the prasugrel group (N=370) or the clopidogrel group (N=372) (LD group: N=269 for prasugrel vs. N=266 for clopidogrel; MD group: N=101 for prasugrel vs. N=106 for clopidogrel). Patients started with the LD were given a LD of either prasugrel 20 mg or clopidogrel 300 mg followed by a daily MD of either prasugrel 3.75 mg or clopidogrel 75 mg. Patients started with the MD were given a MD of prasugrel 3.75 mg or clopidogrel 75 mg for at least 14 days before undergoing PCI.
About prasugrel
Prasugrel is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery. In Japan, Daiichi Sankyo and Ube Industries are co-developing prasugrel. Outside of Japan, based on the co-development by Daiichi Sankyo and Eli Lilly and Company, the European Commission and the FDA granted marketing authorization for prasugrel for the prevention of atherothrombotic events in patients with ACS undergoing PCI, in combination with aspirin, in 2009. To date prasugrel has been approved in more than 70 countries worldwide.
{nextpage}About Elective PCI
Elective PCI is undertaken in patients who have been diagnosed with coronary artery disease (stable angina or history of previous myocardial infarction, or myocardial infarction), and in whom coronary stenosis and blockage have been confirmed.
About Acute Coronary Syndrome
Acute coronary syndrome includes heart attacks and unstable angina (chest pain). Heart attack is a major manifestation of coronary heart disease, which occurs when the arteries become narrowed or clogged by cholesterol and fat deposits. In some cases the plaque can rupture, resulting in a blood clot which may partially or totally block the blood supply to portions of the heart, resulting in ACS5.
(责任编辑:lili.zhao)
作者:tomato
版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#III#
48
#积极数据#
54
#ACS#
52
#III期#
56